| Revenue growth | FY26 revenue stagnant at ₹1,713cr; Q4 revenue ₹519cr. |
|---|---|
| Margins | Sequential EBITDA margin improvement to 20.3% in Q4. |
| Order book | Order book intact; healthy RFP activity in CDMO segments. |
| Demand visibility | Improving demand trends in Pharma; Crop Protection seeing inventory normalization. |
| Management confidence | Cautiously optimistic but defensive regarding USFDA and previous guidance misses. |
Growth
FY26 revenue of ₹1,713cr shows long-term stagnation; Q4 EBITDA margins improved to 20.3% sequentially.
Outlook
Targeting 5-6 DMF filings annually; FY27 guidance deferred to Q1 results due to geopolitical uncertainty.
Risks
USFDA warning letter at Bangalore site; high raw material volatility; major asset impairment at Panoli.
Earnings Call filed with BSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹217.58
- Market cap
- ₹2,683 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -79.4×Sector 50.4×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 0.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Annual General Meeting
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal Production Started
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Earnings Call Transcript: Key Takeaways
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
- Call
- Guides 15% growth
Hikal Investor Presentation: Key Takeaways
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Q1 FY27 Results: Net Loss of ₹7.4 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹402.8 Cr (+5.9% YoY) and a net loss of ₹7.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹7.4 Cr
Hikal Earnings Call: Key Takeaways
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.